# Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.

> **NCT00225264** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 458 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Pioglitazone
- **DRUG:** Glimepiride

## Key facts

- **NCT ID:** NCT00225264
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** 458 (ACTUAL)
- **Last updated:** 2012-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00225264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00225264, "Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00225264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*